HC Wainwright keeps Roivant at Buy; raises PT to $47
HC Wainwright & Co. maintained Roivant Sciences at Buy and raised its price target to $47.00 per share from $41.00, according to Benzinga ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.